Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLOT + trastuzumab + pertuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) with the monoclonal antibodies trastuzumab and pertuzumab is an investigational regimen for the perioperative treatment of HER2-positive resectable gastric or gastroesophageal junction adenocarcinoma. Trastuzumab and pertuzumab are both HER2-targeted monoclonal antibodies that bind to different epitopes on the human epidermal growth factor receptor 2 (HER2), inhibiting its signaling and promoting antibody-dependent cellular cytotoxicity. The addition of these agents to standard FLOT chemotherapy has demonstrated improved pathologic complete response rates and nodal negativity in clinical trials but is associated with increased toxicity such as diarrhea and leukopenia[2][3][4][5]. This regimen is not currently approved for this indication but has been studied in phase II/III trials such as PETRARCA (NCT02581462) and HERFLOT.
- Other names
- fluorouracil + leucovorin + oxaliplatin + docetaxel + trastuzumab + pertuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on FLOT + trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLOT + trastuzumab + pertuzumab.